| (Values in U.S. Thousands) | Mar, 2026 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 |
| Sales | 156,644 | 253,273 | 163,887 | 171,235 | 199,978 |
| Sales Growth | -38.15% | +54.54% | -4.29% | -14.37% | -9.61% |
| Net Income | -121,936 | 14,624 | -43,087 | -43,478 | -31,577 |
| Net Income Growth | -933.81% | +133.94% | +0.90% | -37.69% | +22.68% |
Evotec Se (EVT.D.DX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Fiscal Year End Date: 12/31